The Atrial Fibrillation Devices Market To Witness An Extensive Growth With A CAG

Posted by Ashish on January 4th, 2021

Interventional electrophysiology devices have already had a significant impact on patients suffering from cardiac arrhythmias, and are being increasingly adopted as a permanent treatment option for atrial fibrillation. Procedures such as radiofrequency ablation, cryoablation, and cox-maze are well performed in today’s practice.

Recent studies have found cryoablation to be more effective than medical management, and it is widely used in medical surgical practice. The overall market is primarily driven by the growing prevalence of atrial fibrillation amongst the geriatric as well as adult population, and the adoption of minimally-invasive techniques for the permanent treatment of atrial fibrillation.

Moreover, the use of innovative techniques, advancements in technology, and favorable reimbursement scenario are some other factors responsible for propelling the growth of the atrial fibrillation devices market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31531

Companies covered in Atrial Fibrillation Devices Market Report

  • Biosensense Webster, Inc. (Johnson & Johnson)
  • Abbott Laboratories
  • Medtronic Plc
  • Boston Scientific Corporation
  • AtriCure, Inc.
  • Japan Lifeline Co.
  • Biotronik, Inc
  • MicroPort Scientific Corporation
  • Biomerics
  • CathRx

Like it? Share it!


Ashish

About the Author

Ashish
Joined: September 12th, 2019
Articles Posted: 582

More by this author